Stenger Family Office’s Vertex Pharmaceuticals VRTX Stock Holding History

Stenger Family Office’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$374K	Sell	752 -7,148	-90%	-$3.17M	0.06%	97
2026 Q1	$3.53M	Buy	7,900 +577	+8%	+$269K	0.62%	40
2025 Q4	$3.32M	Sell	7,323 -3,398	-32%	-$1.46M	0.69%	39
2025 Q3	$4.5M	Buy	+10,721	New	+$4.48M	0.92%	32

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Stenger Family Office's VRTX Position: Q2 2026 in Review

Stenger Family Office reduced its Vertex Pharmaceuticals (VRTX) stake by 90% in Q2 2026, selling an estimated $3.17M and leaving 752 shares worth $374K. The position accounts for 0.06% of the portfolio, ranked #97.

Stenger Family Office first reported a position in VRTX in Q3 2025 and has held it in 4 quarters since. The position peaked at $4.5M in Q3 2025. 429 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Stenger Family Office held 752 shares of Vertex Pharmaceuticals worth $374K as of Q2 2026.
Stenger Family Office sold 7,148 Vertex Pharmaceuticals shares in Q2 2026, an estimated $3.17M.
Vertex Pharmaceuticals made up 0.06% of Stenger Family Office's portfolio in Q2 2026, its #97 holding.
Stenger Family Office first reported a position in Vertex Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
Stenger Family Office's Vertex Pharmaceuticals position peaked at $4.5M in Q3 2025.
429 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Stenger Family Office's 13F filing for Q2 2026, filed 13 Jul 2026.